Screener
BioCryst Pharmaceuticals BCRX Amortization of premium (discount) on investments, net
Amortization of premium (discount) on investments, net at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept bcrx:AmortizationOfPremiumDiscountOnInvestments.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Payment of Pharmakon paid-in-kind interest | — | (5,492) |
| Non-cash interest expense on royalty financing obligations | 26,330 | 26,916 |
| Amortization of debt issuance costs on term loans | 352 | 1,003 |
| Amortization of discount on investments, net | (166) | (2,533) |
| Loss on extinguishment of debt | — | 4,171 |
| Changes in operating assets and liabilities: | ||
| Increase in trade receivables | (1,959) | (21,295) |
| (Increase) decrease in inventory | (9,196) | 568 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's amortization of premium (discount) on investments, net?
- BioCryst Pharmaceuticals (BCRX) reported amortization of premium (discount) on investments, net of -$417K in Q2 2026.
- How has BioCryst Pharmaceuticals's amortization of premium (discount) on investments, net changed year-over-year?
- BioCryst Pharmaceuticals's amortization of premium (discount) on investments, net increased by 63.7% year-over-year, from -$1.15M to -$417K.
- What is the long-term trend for BioCryst Pharmaceuticals's amortization of premium (discount) on investments, net?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's amortization of premium (discount) on investments, net has grown at a 582.2% compound annual growth rate (CAGR), from -$2K to -$4.33M.
- What does amortization of premium (discount) on investments, net mean?
- Reflects the non-cash adjustment to the carrying value of investment securities to account for the amortization of premiums or the accretion of discounts over the holding period. This adjustment aligns the reported interest income with the effective yield of the investment portfolio. It is a standard accounting practice used to normalize investment returns on the income statement.
Ask your AI about BioCryst Pharmaceuticals's amortization of premium (discount) on investments, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude